Related Experiment Video
Updated: Jan 22, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Analysis of inequality in nanomedicine using clinical trials and disease burden
Thomas Woodson1, Victor Rodriguez2
1Department of Technology & Society, Stony Brook University, 1412 Computer Science, Stony Brook, NY 11794, USA.
Abstract:
Aim: This study explores the impact nanomedicine will have on global health, poverty and inequality. Materials & methods: Using a nanotechnology search strategy, the team extracted nanotechnology clinical trials (CT) from the dataset clinicaltrials.gov. The team then combined CT with information about burden of disease data from the Institute of Health Metrics and Evaluation. Finally, the team ran regression analyses to determine whether nanotechnology CT are decreasing inequality compared with non-nanotechnology CT. Results & conclusion: Nanomedicine and non-nanomedicine CT follow similar research patterns. In general, nanomedicine is neither increasing nor decreasing the technological gap between countries in the global North and South.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Chronic Kidney Disease II: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Coronary Artery Disease III: Clinical Manifestations

